Pat Brooks has become vice president of North American sales of Pacific Biosciences, and Randy Livingston has joined the company’s board of directors.
Prior to joining PacBio, Brooks was vice president of sales for Affymetrix. Before that, he held various sales positions at Amersham/Pharmacia, formerly AP Biotech, including that of vice president of sales and marketing for drug discovery. Previously, he worked in sales and sales management for several life science companies, including Millipore, DuPont-NEN, and Sargent Welch Scientific. Brooks holds MS and BS degrees from the University of Iowa.
Livingston is vice president for business affairs and CFO of Stanford University. Prior to that, he spent 16 years as a finance, marketing, and corporate development executive for several Silicon Valley companies, and six years as a consultant at McKinsey. He is also a director of Genomic Health, eHealth, and the Stanford Management Company. Livingston holds an MBA from the Stanford Graduate School of Business and a BS in mechanical engineering from Stanford University.
Francis Collins and Craig Venter are among nine researchers President Obama has named as recipients of the National Medal of Science this year. They will receive the award on Oct. 7 at a White House ceremony.
Collins recently became the director of the National Institutes of Health. Prior to that, he was the director of the National Human Genome Research Institute.
Venter is the founder, president, and chairman of the J. Craig Venter Institute as well as the founder and CEO of Synthetic Genomics.
Stan Rose has joined the board of directors of NABsys. He is the president of Rose Ventures, which provides consulting services and manages a portfolio of public and private equity investments. Previously, he was as CEO of NimbleGen Systems, now part of Roche, and before that, he co-founded Genetic Microsystems, which was acquired by Affymetrix in 2000. Prior to that, he led the PCR business for PerkinElmer and Applied Biosystems in the 1990s. Rose holds a PhD from the Massachusetts Institute of Technology and a BA from Cornell University.
Charles Lee and David Barker have become advisors to BioNanomatrix.
Lee, an experts in structural genomic variation, is the director of cytogenetics for the Harvard Cancer Center, an associate professor of pathology at Harvard Medical School, and an associate member of the Broad Institute. He is also an adjunct associate professor at the Chinese University of Hong Kong. Lee holds a PhD from the University of Alberta.
Barker is the former vice president and CSO of Illumina and is still a member of the firm’s scientific advisory board. Prior to Illumina, he was vice president and chief science advisor at Amersham Biosciences, now part of General Electric. Before that, he held several positions, including that of vice president of research and business development, at Molecular Dynamics. Earlier, he was an assistant professor at the University of Oregon and an associate professor at Oregon State University. Barker holds a PhD from Brandeis University and a BS from the California Institute of Technology.
Michael Critelli has joined the board of directors of Navigenics. He recently retired from Pitney Bowes, a company with expertise in secure business communications, where he used to be CEO and chairman.
Mark Boguski has become a science advisor to GenomeQuest. He is an associate professor in the Center for Biomedical Informatics at Harvard Medical School.